FK949E

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Mar 26, 2012 โ†’ Jun 22, 2012

About FK949E

FK949E is a phase 1 stage product being developed by Astellas Pharma for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01919008. Target conditions include Major Depressive Disorder.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (7)

NCT IDPhaseStatus
NCT02362412Phase 3Completed
NCT01737268Phase 3Completed
NCT01919008Phase 1Completed
NCT01924520Phase 1Completed
NCT01903200Phase 1Completed
NCT01871987Phase 1Completed
NCT01871974Phase 1Completed

Competing Products

20 competing products in Major Depressive Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33
LY2216684 + Placebo + LorazepamEli LillyPhase 1
33
LY2216684 + SSRIEli LillyPhase 3
77
DuloxetineEli LillyApproved
85